Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

09:00 EDT 5 Jul 2017 | Businesswire

This article has expired, however you can still download the PDF.
Scientific Journal Acta Neuropathologica publishes pre-clinical data Prana Biotechnology Ltd (NASDAQ: PRAN) (ASX: PBT) today announced the article “The novel compound PBT434 prevents iron-mediated neurodegeneration and alp...

Other Sources for this Article

Investor Relations
WE Buchan
Rebecca Wilson, +61 3 9866 4722
WE Buchan
Scott Newstead, +61 3 9866 4722


More From BioPortfolio on "Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration"

Quick Search


Relevant Topics

Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Mental Health
Adhd Anorexia Depression Dyslexia Mental Health Psychiatry Schizophrenia Stress Mental health, although not being as obvious as physical health, is very important, causing great unhappiness to those affected, causing add...